The US drug regulator conducted good manufacturing practice (GMP) and pre-approval inspection at R&D centre in Bachupally, Hyderabad from 4 December 2023 to 8 December 2023.
Upon completion, the durg maker has been issued a Form 483 with three observations, which it will address within the stipulated timeline.
Dr. Reddy's Laboratories is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products.
The pharma company's consolidated net profit surged 33.0% YoY to Rs 1482.20 crore on 9.1% rise in net sales to Rs 6880.20 crore in Q2 FY24 over Q2 FY23.
Shares of Dr. Reddy's Laboratories shed 0.36% to end at Rs 5,763.50 on Friday, 8 December 2023.
Powered by Capital Market - Live News